RIVAROXABAN USERS HAVE SIGNIFICANTLY LESS TREATMENT DISCONTINUATION COMPARED WITH USERS OF OTHER ORAL ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION
| Autor: | Willy Wynant, Colleen McHorney, Eric Peterson, Patrick Lefebvre, Jeffrey Schein, François Laliberté, Concetta Crivera, Guillaume Germain, Veronica Ashton |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Rivaroxaban
medicine.medical_specialty business.industry Non valvular atrial fibrillation Atrial fibrillation macromolecular substances medicine.disease Persistence (computer science) Discontinuation Internal medicine cardiovascular system medicine Cardiology cardiovascular diseases Cardiology and Cardiovascular Medicine Adverse effect business medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 69:206 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/s0735-1097(17)33595-7 |
| Popis: | Background: In non-valvular atrial fibrillation (NVAF) patients, persistence on oral anticoagulants (OACs) is important to prevent potentially severe adverse events. Objective: To evaluate persistence on therapy and to compare time to discontinuation among NVAF patients using OACs. Methods: IMS |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|